OSCO serves as the hub for oncology-related news and advances in Oklahoma. Our organization is made up of clinics and healthcare professionals working together to safeguard the rights of patients and to maintain high medical and ethical standards in the industry.
Merck is pleased to announce that KEYTRUDA® (pembrolizumab) has been approved by the FDA for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. · PD-L1 diagnostic testing is not required prior to […]
Read More...OSCO members are invited to join your peers for an exciting live broadcast event on February 5 at Vast Restaurant featuring an expert-led discussion presented by Hope Rugo, MD. exploring newly approved ENHERTU® therapy for adult patients with unresectable or metastatic HER2-positive breast cancer. Contact Tara O’Mahony for more information and to RSVP at [email protected]
Read More...Taiho Oncology announced that is offering a new patient assistance program where eligible patients pay $0 per treatment plan. Patients who are reimbursed under Medicaid, a Medicare drug benefit program, Tricare, or other state or federal programs are not eligible. To determine patient eligibility, go to or call: TaihoOncologyCopay.com or phone (844) TAIHO-4U (844-824-4648).
Read More...Join OSCO for the Official Best of San Antonio Breast Cancer Symposium® designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease.
Your company can sponsor OSCO and the work we do by becoming a corporate member today! For more information or to sign up, contact Kathy Musson, OSCO Executive Director at [email protected] or by phone at 405-850-8334.
The Oklahoma Society of Clinical Oncology (OSCO) is Oklahoma’s only professional organization that represents all those in oncology. Our membership works to advance the sciences of hematology and oncology and its sub-specialties, and to improve services to the public by studying the socio-economic aspects of the practice of our members.
